Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014
Safoura Sheikh Rezaei, Angelika Geroldinger, Georg Heinze, et al.
International Journal of Cardiology (2017) Vol. 235, pp. 61-66
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
Dirk Sibbing, Dániel Aradi, Claudius Jacobshagen, et al.
The Lancet (2017) Vol. 390, Iss. 10104, pp. 1747-1757
Open Access | Times Cited: 524
H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review
Aws Almufleh, F. Daniel Ramirez, Derek So, et al.
Cardiology (2018) Vol. 140, Iss. 2, pp. 115-123
Open Access | Times Cited: 26
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
Kamil F. Faridi, Kirk N. Garratt, Kevin F. Kennedy, et al.
Circulation Cardiovascular Quality and Outcomes (2020) Vol. 13, Iss. 3
Open Access | Times Cited: 18
Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials
Pravesh Kumar Bundhun, Jiaxin Shi, Feng Huang
BMC Pharmacology and Toxicology (2017) Vol. 18, Iss. 1
Open Access | Times Cited: 18
Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations
Piotr Adamski, Urszula Adamska, Małgorzata Ostrowska, et al.
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 13, pp. 1415-1425
Closed Access | Times Cited: 17
Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y12 inhibitors in a large observational study
Jeong Cheon Choe, Kwang Soo, Jinhee Ahn, et al.
International Journal of Cardiology (2018) Vol. 274, pp. 21-26
Closed Access | Times Cited: 17
Prognostic Impact of CYP2C19 Genotypes on Long‐Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention
Ju Hyeon Kim, Seung‐Jun Lee, Jung‐Joon Cha, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 10
Open Access | Times Cited: 1
Impact of proton pump inhibitor use on clinical outcomes in East Asian patients receiving clopidogrel following drug-eluting stent implantation
Ju Hyeon Kim, Soon Jun Hong, Jung‐Joon Cha, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Real-world incidence of patient-reported dyspnoea with ticagrelor
A. Prosser, Jessica L. Dawson, KethLyn Koo, et al.
Therapeutic Advances in Drug Safety (2018) Vol. 9, Iss. 10, pp. 577-584
Open Access | Times Cited: 12
Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention
Michela Faggioni, Usman Baber, Jaya Chandrasekhar, et al.
International Journal of Cardiology (2018) Vol. 275, pp. 31-35
Open Access | Times Cited: 12
Real-World Bleeding and Ischemic Events in Asian Patients on P2Y12-Inhibitors After Percutaneous Coronary Intervention: A National Claims Data Analysis
Yonggu Lee, Young‐Hyo Lim, Yongwhi Park, et al.
Advances in Therapy (2020) Vol. 38, Iss. 1, pp. 562-578
Open Access | Times Cited: 10
Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients
Daniel M.F. Claassens, Marieke E. Gimbel, Thomas O. Bergmeijer, et al.
International Journal of Cardiology (2021) Vol. 334, pp. 10-17
Open Access | Times Cited: 9
A thrombocytaaggregáció-gátló kezelés gyakorlata heveny szívinfarktusban
András Jánosi, Tamás Ferenci, Gábor Bársony, et al.
Orvosi Hetilap (2022) Vol. 163, Iss. 19, pp. 743-749
Open Access | Times Cited: 6
The value of using polymorphisms in anti-platelet therapy
Habib Haybar, Zeinab Deris Zayeri
Frontiers in Biology (2017) Vol. 12, Iss. 5, pp. 349-356
Closed Access | Times Cited: 7
Quality of care for secondary cardiovascular disease prevention in 2009–2017: population-wide cohort study of antiplatelet therapy use in Scotland
Inna Thalmann, David Preiss, Iryna Schlackow, et al.
BMJ Quality & Safety (2023) Vol. 33, Iss. 11, pp. 716-725
Open Access | Times Cited: 2
Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention
Yaron Arbel, Maria C. Bennell, Shaun G. Goodman, et al.
Canadian Journal of Cardiology (2017) Vol. 34, Iss. 1, pp. 31-37
Closed Access | Times Cited: 5
Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry
M. Rasia, Emilia Solinas, Massimiliano Marino, et al.
Journal of Thrombosis and Thrombolysis (2017) Vol. 44, Iss. 4, pp. 466-474
Closed Access | Times Cited: 4
Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach
Asim N. Cheema
Current Vascular Pharmacology (2018) Vol. 17, Iss. 2, pp. 119-122
Closed Access | Times Cited: 3
Trends in dual antiplatelet therapy regimens and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention with drug‐eluting stents: A multicenter real‐world study
Preyanate Wilairat, Arintaya Phrommintikul, Thanyalak Chotayaporn, et al.
Chronic Diseases and Translational Medicine (2024) Vol. 11, Iss. 1, pp. 57-68
Open Access
Prescribing Trends and Health Care Expenditure of P2Y12 Prescriptions in Australia Over the Last Decade
Timothy Abrahams, Adam Brown, D. Pol
Heart Lung and Circulation (2022) Vol. 31, Iss. 10, pp. 1369-1375
Closed Access | Times Cited: 2
Cost-effectiveness of prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention
Μichael Spartalis, Eleni Tzatzaki, Nikolaos Nikiteas, et al.
International Journal of Cardiology (2017) Vol. 251, pp. 32-32
Closed Access | Times Cited: 1
Experience with Prasugrel in the Treatment of Patients with Acute Coronary Syndrome
И. И. Староверов, И. Б. Меркулова, É. A. Avetisyan
Kardiologiia (2019) Vol. 59, Iss. 6, pp. 18-25
Open Access | Times Cited: 1
Comparison of Clinical Outcomes in Acute Coronary Syndrome Patients Who Undergo Percutaneous Coronary Intervention Using Different P2Y12 Inhibitors: A SMS Hospital Based Observational Study
Raghuraj Swami, Sohan Kumar Sharma, P. N. Meena
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
The Use Pattern and Clinical Impact of Novel P2Y12 Receptor Antagonists for Acute Myocardial Infarction in Korea
Soo–Joong Kim
Korean Circulation Journal (2017) Vol. 47, Iss. 6, pp. 864-864
Open Access
Novel Antithrombotic Drugs and Intraocular Bleeding
Daniel Caldeira
JAMA Ophthalmology (2017) Vol. 136, Iss. 2, pp. 130-130
Closed Access
Page 1 - Next Page

Scroll to top